

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百信集团
PASHUN GROUP

Pa Shun International Holdings Limited
百信國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING
REGARDING CO-OPERATION IN PHARMACEUTICAL BUSINESS

The Company is pleased to announce that on 16 May 2024, it entered into a memorandum of understanding (the “**MoU**”) with Hongtai Pharmaceutical Technology Company Limited* (泓泰医药科技有限公司) (“**Hongtai Pharmaceutical**”), a company incorporated in the People’s Republic of China (the “**PRC**”). The principal activities of Hongtai Pharmaceutical are GAP management of Chinese medicine materials, research and development and sales of proprietary Chinese medicines, and overseas export of in-hospital preparations which covers the entire Chinese medicine industry chain. Hongtai Pharmaceutical currently has four innovative traditional Chinese medicines that have completed Phase II clinical trials in China.

According to the MoU, the Company and Hongtai Pharmaceutical intend to have in-depth co-operation in Chinese medicine research and development, production and distribution.

On behalf of the Board
Pa Shun International Holdings Limited
Yuan Hongbing
Chairman and Executive Director

Hong Kong, 16 May 2024

As at the date of this announcement, the executive Directors are Mr. Yuan Hongbing and Mr. Ma Qinghai; the non-executive Directors are Mr. Chen Zhongzheng and Mr. Zhou Jinkai; and the independent non-executive Directors are Ms. Li Yan and Mr. Khor Khie Liem Alex.